Laboratory Tests for SLE in Pregnancy

Core Laboratory Tests for SLE in Pregnancy

The American College of Rheumatology recommends regular laboratory monitoring of disease activity, including renal function parameters and serological markers, such as serum C3/C4 and anti-dsDNA titers, to monitor for obstetrical adverse outcomes and disease flares in pregnant women with SLE 1, 2
Assessment of disease activity should include laboratory monitoring at least once per trimester, with tests such as complete blood cell count with differential, urinalysis and urinary protein:creatinine ratio, serum C3 and C4 complement levels, and anti-dsDNA antibody titers 3
Serum C3 and C4 complement levels, and anti-dsDNA antibody titers are essential for monitoring disease activity in pregnant women with SLE, as recommended by the European League Against Rheumatism 1, 3
Blood urea nitrogen and urinalysis for proteinuria and urine sediment are important renal function parameters, especially for patients with a history of lupus nephritis, as suggested by the American College of Rheumatology 5
Autoantibody testing, including anti-Ro/SSA and anti-La/SSB antibodies, should be performed once before or early in pregnancy, as strongly recommended by the American College of Rheumatology 4, 6

A baseline assessment, including complete laboratory evaluation, should be performed preconceptionally or early in pregnancy, as recommended by the American College of Rheumatology 4, 3
Laboratory tests should be performed at least once per trimester, with increased frequency based on disease activity, as suggested by the European League Against Rheumatism 3
Vitamin D levels should be measured after pregnancy is confirmed, as recommended by the American College of Rheumatology 1, 7

Positive anti-Ro/SSA and anti-La/SSB results require fetal echocardiography monitoring for congenital heart block, especially in cases of suspected fetal dysrhythmia or myocarditis, as recommended by the American Heart Association 1, 7
The American College of Rheumatology suggests that medication adjustments, particularly for patients on hydroxychloroquine, should be guided by laboratory monitoring, and that hydroxychloroquine should be continued throughout pregnancy 3